Harmony Biosciences (NASDAQ:HRMY) & Eloxx Pharmaceuticals (NASDAQ:ELOX) Financial Contrast

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Harmony Biosciences (NASDAQ:HRMY) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Insider & Institutional Ownership

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Eloxx Pharmaceuticals and Harmony Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Harmony Biosciences	18.88%	20.06%	14.15%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Eloxx Pharmaceuticals and Harmony Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1	0	2	1	2.75
Harmony Biosciences	1	5	5	0	2.36

Eloxx Pharmaceuticals currently has a consensus price target of $41.50, suggesting a potential upside of 150.45%. Harmony Biosciences has a consensus price target of $47.11, suggesting a potential upside of 13.19%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Eloxx Pharmaceuticals is more favorable than Harmony Biosciences.

Risk & Volatility

Eloxx Pharmaceuticals has a beta of -1862.26, indicating that its stock price is 186,326% less volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.

Earnings and Valuation

This table compares Eloxx Pharmaceuticals and Harmony Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36 million	10.53	-$5.99 million	($1.54)	-10.76
Harmony Biosciences	$868.45 million	2.79	$158.69 million	$3.08	13.51

Harmony Biosciences has higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Harmony Biosciences beats Eloxx Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.